孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘的疗效观察
|
摘要
目的:探讨孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘的临床疗效。方法:选取2016年2月至2017年6月郑州大学附属洛阳市中心医院收治的哮喘患者110例作为研究对象,以随机数字表法分为观察组和对照组,每组55例。对照组患者给予沙美特罗替卡松粉吸入剂治疗,观察组患者在对照组的基础上加用孟鲁司特钠片治疗。对比观察两组患者的临床疗效、肺功能指标及不良反应发生情况的差异。结果:观察组患者的总有效率为96.36%(53/55),明显高于对照组的78.18%(43/55),差异有统计学意义(P<0.05);治疗后,观察组患者用力肺活量、1 s用力呼气容积和呼吸峰流速明显优于对照组,差异均有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为9.09%(5/55)、10.91%(6/55),差异无统计学意义(P>0.05)。结论:孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘的疗效显著,可改善患者肺功能,且不良反应少。
OBJECTIVE: To probe into the clinical efficacy of Montelukast sodium tablets combined with salmeterol fluticasone powder inhalation in treatment of asthma. METHODS: 110 patients with asthma admitted into Luoyang Central Hospital Affiliated to Zhengzhou University from Feb. 2016 to Jun. 2017 were selected and divided into observation group and control group via random number table,with 55 cases in each. The control group was treated with salmeterol fluticasone powder inhalation,while the observation group was given Montelukast sodium tablets combined with salmeterol fluticasone powder inhalation. Differences in clinical efficacy,indices of pulmonary function and incidences of adverse drug reactions between two groups were observed and compared. RESULTS: The total effective rate of observation group was 96. 36%( 53/55),which was significantly higher than that of the control group( 78. 18%,43/55),with statistically significant difference( P < 0. 05); after treatment,the forced vital capacity( FVC),forced expiratory volume in 1 s( FEV1) and peak expiratory flow rate( PEFR) of observation group were significantly better than those of the control group,with statistically significant differences( P < 0. 05); the incidences of adverse drug reactions of observation group and control group were respectively 9. 09%( 5/55) and 10. 91%( 6/55),the difference had no statistical significance( P > 0. 05). CONCLUSIONS: The efficacy of Montelukast sodium tablets combined with salmeterol fluticasone powder inhalation in treatment of asthma,which can improve patients' pulmonary function,with few adverse drug reactions.
OBJECTIVE: To probe into the clinical efficacy of Montelukast sodium tablets combined with salmeterol fluticasone powder inhalation in treatment of asthma. METHODS: 110 patients with asthma admitted into Luoyang Central Hospital Affiliated to Zhengzhou University from Feb. 2016 to Jun. 2017 were selected and divided into observation group and control group via random number table,with 55 cases in each. The control group was treated with salmeterol fluticasone powder inhalation,while the observation group was given Montelukast sodium tablets combined with salmeterol fluticasone powder inhalation. Differences in clinical efficacy,indices of pulmonary function and incidences of adverse drug reactions between two groups were observed and compared. RESULTS: The total effective rate of observation group was 96. 36%( 53/55),which was significantly higher than that of the control group( 78. 18%,43/55),with statistically significant difference( P < 0. 05); after treatment,the forced vital capacity( FVC),forced expiratory volume in 1 s( FEV1) and peak expiratory flow rate( PEFR) of observation group were significantly better than those of the control group,with statistically significant differences( P < 0. 05); the incidences of adverse drug reactions of observation group and control group were respectively 9. 09%( 5/55) and 10. 91%( 6/55),the difference had no statistical significance( P > 0. 05). CONCLUSIONS: The efficacy of Montelukast sodium tablets combined with salmeterol fluticasone powder inhalation in treatment of asthma,which can improve patients' pulmonary function,with few adverse drug reactions.
引文
[1]刘玉玲.孟鲁司特联合舒利迭治疗哮喘的临床效果观察[J].医药前沿,2017,7(22):101.
[2]孙安凤.舒利迭联合孟鲁司特钠对哮喘的临床疗效观察[J].吉林医学,2015,36(7):1386-1387.
[3]宁小平,何东阳,戴广标.舒利迭单用与合用孟鲁司特对老年哮喘的实效性对比[J].临床医学,2016,36(3):45-46.
[4]刘海波.孟鲁司特联合舒利迭治疗哮喘的临床疗效分析[J].中国保健营养,2016,26(30):244.
[5]解颖.孟鲁司特联合舒利迭治疗哮喘的临床疗效[J].中国保健营养,2016,26(28):123.
[6]吴柳晴.孟鲁司特联合舒利迭治疗哮喘的可行性观察[J].健康前沿,2017,26(5):195-196.
[7]王英姿.舒利迭及孟鲁司特联合治疗重度哮喘的临床效果分析[J].吉林医学,2014,35(9):1880.
[8]王喜莲,刘飞.舒利迭气雾剂及氟替卡松气雾剂联合孟鲁司特钠口服治疗哮喘的临床效果分析[J].中国现代医生,2017,55(35):108-110.
[9]丁庆辉.孟鲁司特联合舒利迭治疗哮喘的临床疗效及对Th17、调节性T细胞平衡和IL-4、IFN-γ表达的影响[J].菏泽医学专科学校学报,2017,29(4):33-35,70.
[10]毛伟长.孟鲁司特联合沙美特罗替卡松治疗儿童支气管哮喘效果观察[J].中国乡村医药,2017,24(22):31-32.
[11]赵世英.口服孟鲁司特钠联合吸入沙美特罗替卡松治疗支气管哮喘的疗效及安全性[J].中国实用医药,2017,12(30):142-143.
[12]谭文烽,唐兴娟.沙美特罗氟替卡松联合孟鲁司特钠治疗慢性阻塞性肺疾病急性加重期临床疗效观察[J].现代医药卫生,2017,33(16):2513-2515.
[13]彭惠忠.沙美特罗替卡松粉吸入剂结合孟鲁司特钠治疗支气管哮喘患者的临床效果观察[J].现代实用医学,2017,29(8):1046-1048.
[2]孙安凤.舒利迭联合孟鲁司特钠对哮喘的临床疗效观察[J].吉林医学,2015,36(7):1386-1387.
[3]宁小平,何东阳,戴广标.舒利迭单用与合用孟鲁司特对老年哮喘的实效性对比[J].临床医学,2016,36(3):45-46.
[4]刘海波.孟鲁司特联合舒利迭治疗哮喘的临床疗效分析[J].中国保健营养,2016,26(30):244.
[5]解颖.孟鲁司特联合舒利迭治疗哮喘的临床疗效[J].中国保健营养,2016,26(28):123.
[6]吴柳晴.孟鲁司特联合舒利迭治疗哮喘的可行性观察[J].健康前沿,2017,26(5):195-196.
[7]王英姿.舒利迭及孟鲁司特联合治疗重度哮喘的临床效果分析[J].吉林医学,2014,35(9):1880.
[8]王喜莲,刘飞.舒利迭气雾剂及氟替卡松气雾剂联合孟鲁司特钠口服治疗哮喘的临床效果分析[J].中国现代医生,2017,55(35):108-110.
[9]丁庆辉.孟鲁司特联合舒利迭治疗哮喘的临床疗效及对Th17、调节性T细胞平衡和IL-4、IFN-γ表达的影响[J].菏泽医学专科学校学报,2017,29(4):33-35,70.
[10]毛伟长.孟鲁司特联合沙美特罗替卡松治疗儿童支气管哮喘效果观察[J].中国乡村医药,2017,24(22):31-32.
[11]赵世英.口服孟鲁司特钠联合吸入沙美特罗替卡松治疗支气管哮喘的疗效及安全性[J].中国实用医药,2017,12(30):142-143.
[12]谭文烽,唐兴娟.沙美特罗氟替卡松联合孟鲁司特钠治疗慢性阻塞性肺疾病急性加重期临床疗效观察[J].现代医药卫生,2017,33(16):2513-2515.
[13]彭惠忠.沙美特罗替卡松粉吸入剂结合孟鲁司特钠治疗支气管哮喘患者的临床效果观察[J].现代实用医学,2017,29(8):1046-1048.